Skip to main content
CELU
NASDAQ Life Sciences

Celularity Seeks Nasdaq Approval for Convertible Note Shares; 10% Price Cut if Vote Fails

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$0.98
Mkt Cap
$30.507M
52W Low
$0.56
52W High
$2.55
52W Position info
75% above low
Off High info
62% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

CELU sits 75% above its 52-week low of $0.56 on light trading volume (0.1× avg).

Summary

Celularity's preliminary proxy asks shareholders to approve the full share issuance under its September 2026 convertible note financing for Nasdaq purposes, with a 10% conversion and exercise price cut triggered if approval is not obtained by December 19, 2026.


Key Events · Financing and Capital Events · CELU

  • Nasdaq Vote on Convertible Note Shares

    Shareholders are asked to approve, for Nasdaq Listing Rule 5635, the full issuance of Class A common stock upon conversion of the notes and exercise of the warrants from the September 23, 2026 Securities Purchase Agreement, which allows up to $25.0 million of senior secured convertible notes in two tranches.

  • 10% Price Cut if Vote Fails

    If the required stockholder approval is not obtained on or prior to December 19, 2026, the then-current conversion price of each outstanding note and exercise price of each outstanding warrant automatically drops 10%, effective December 20, 2026 — increasing the shares issuable.

  • Initial Tranche Already Funded

    The initial closing on September 24, 2026 issued roughly $11.01 million of notes convertible into about 7,340,000 shares plus warrants for about 4,037,000 shares, all at an initial $1.50 conversion and exercise price versus today's $0.98 stock price.

  • Equity Plan Reserve Increase

    A separate proposal would add 3,500,000 shares to the 2021 Equity Incentive Plan, raising the reserve to 4,479,204 shares; only 178,154 shares remained available as of December 31, 2025.


Analysis · CELU · Life Sciences

Celularity is asking shareholders to bless the full share issuance behind its September 2026 convertible financing, a Nasdaq Rule 5635(d) requirement rather than a new deal. The stakes are concrete: if approval is not in hand by December 19, 2026, every outstanding note conversion price and warrant exercise price drops 10% automatically on December 20, 2026, so a failed vote directly increases the share count issued to the lenders. Because the notes are already binding obligations, a 'no' vote does not undo the debt — it only limits how many shares the company can deliver and makes the eventual conversion cheaper for the holders. Against a going-concern backdrop with only $0.6M of cash reported in the Q2 2026 10-Q, the proxy also asks for 3,500,000 more shares under the 2021 Equity Incentive Plan, adding a second layer of dilution on top of the financing.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CELU was trading at $0.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $30.5M. The 52-week trading range was $0.56 to $2.55. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CELU - Latest Insights

CELU
Nov 10, 2026, 4:30 PM EST
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $0.720
Real-time Price: $0.630 info
Change: -$0.090 (-12%) info
Market Cap: $20.447M info
CELU
Oct 20, 2026, 5:08 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $1.26
Real-time Price: $0.630 info
Change: -$0.630 (-50%) info
Market Cap: $20.447M info
CELU
Oct 05, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.62
Real-time Price: $0.630 info
Change: -$0.985 (-61%) info
Market Cap: $20.447M info
CELU
Sep 29, 2026, 5:02 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $1.39
Real-time Price: $0.630 info
Change: -$0.760 (-55%) info
Market Cap: $20.447M info
CELU
Sep 28, 2026, 1:14 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $1.39
Real-time Price: $0.630 info
Change: -$0.760 (-55%) info
Market Cap: $20.447M info